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Introduction: In sub-Saharan Africa, considerable HIV-burden exists among women. Anti-retroviral (ARV) based
prevention products could decrease this burden, and their uptake could be increased if they also protect against
pregnancy and sexually transmitted infections (STI).
Methods: A discrete choice experiment (DCE) was undertaken in South Africa (2015) through a household survey
of adult females (n = 158) and adolescent girls (n = 204) who self-reported HIV-negative status. The DCE was used to
project the uptake (percentage using product) of oral pre-exposure prophylaxis (PrEP), vaginal rings, and injectable
long-lasting ARV agents among these women, and how uptake could depend on whether these products protect
against pregnancy or STI acquisition. Uptake estimates were used to model how each product could decrease a
women’s HIV acquisition risk.
Results: In adolescent women, there will be limited uptake (< 6% for any product) and impact (< 4% decrease in
HIV acquisition risk) of new products unless they provide pregnancy protection, which could quadruple use and
impact. Adult women have weaker preference for pregnancy protection, with moderate use (< 17% for each) and
impact (< 14 percentage point decrease) if they only provide HIV protection. All women had highest preference for
injectable ARVs, with oral PrEP having high preference if injectable ARVs are not available. Adult women will use the
ring, but adolescent women will not. Importantly, even with three additional prevention products, all providing
pregnancy and STI protection, > 14% of women will remain unprotected and > 31% of the baseline acquisition risk
will remain.
(Continued on next page)© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Peter.Vickerman@bristol.ac.uk
1Population Health Sciences, University of Bristol, Bristol BS8 2BN, UK
Full list of author information is available at the end of the article
Vickerman et al. BMC Infectious Diseases          (2020) 20:704 Page 2 of 11(Continued from previous page)
Conclusions: Incorporating multiple prevention components into new ARV-based prevention products may
increase their uptake and impact among women.
Keywords: HIV, South Africa, Women, Pre-exposure prophylaxis, Vaginal ring, Injectable long-lasting ARV agentsIntroduction
In sub-Saharan Africa, considerable HIV burden exists
amongst adolescent and adult women, accounting for
59% of new infections among adults in 2018 [1, 2].
Young women (15–24 years) in sub-Saharan Africa are
more than twice as likely to acquire HIV than males of
the same age [2]. Until recently, the only female con-
trolled HIV prevention option was the female condom,
which has limited availability and uptake [3, 4]. Other-
wise, the male condom needs active participation of the
male partner which can be problematic, particularly in
casual relationships where power imbalances can make
it difficult for young women to ensure that a condom is
used [5, 6].
Biomedical HIV prevention products emerged after
the HPTN 052 trial found that antiretroviral therapy
(ART) dramatically reduced the infectiousness of HIV
positive persons [7]. Although effective if used adher-
ently, HIV treatment is not a panacea. For HIV-negative
individuals in sero-discordant relationships to be pro-
tected, they must rely on their partner adhering to treat-
ment, something that is not always achieved [8, 9]. For
this reason, HIV treatment cannot be seen as an effect-
ive individual-level prevention method except in long-
term relationships.
Oral pre-exposure prophylaxis (PrEP) is efficacious at
reducing the risk of HIV acquisition amongst women
when used adherently, as shown by a systematic review
of trial data from 2016 [10]. However, trials have shown
that young women can find it difficult to achieve this
protection, with randomised controlled trials from sub-
Saharan Africa showing low adherence and retention
and, ultimately, no reduction in HIV acquisition risk
amongst female users [11, 12]. Although recent demon-
stration projects among adolescent girls and young
women in sub-Saharan Africa have shown similar
difficulties in retention, higher adherence has been
achieved [13]. Despite the efficacy of oral PrEP, there is
an increasing realisation that multiple prevention op-
tions are needed to meet the varied lifestyles of potential
users [14].
Preferences for products may vary by population
group, and a combination approach may be needed to
fulfil a women’s varied needs [15, 16]. In addition to
PrEP, which is now available in South Africa, a number
of longer-lasting products are in development [17, 18],
with some likely becoming available in the next 5 years.These products may reduce the adherence and retention
issues that exist for oral PrEP, which either must be
taken daily or before and after sex. Longer-lasting prod-
ucts include the dapivirine vaginal ring that trials have
shown can be effective at preventing HIV transmission
[19], and injectable long-acting antiretroviral (ARV)
agents which are currently in trial [20]. Unfortunately, in
both existing trials of vaginal rings, younger women
(18–21 years) had low adherence and efficacy [21, 22],
although encouraging new data from open label exten-
sions to these trials suggest higher efficacy [23]. The first
trial of long-acting, injectable PrEP has also recently
shown efficacy in men who have sex with men [24].
Models can be useful for projecting the impact of new
prevention products [25–28]. However, before a product
is used in a real-life setting it is difficult to predict how
the product will be used, and how it will affect the use
of other products. Indeed, even if a product has been
evaluated in a trial setting, it is still hard to understand
how it will be used in real-life. On one hand, it may be
used more than in the trial because it has demonstrated
efficacy, or conversely it may be used less because there
will be less follow-up to ensure adherence compared to
during a trial.
Trials also tell us little about how variations in the
characteristics of different products may affect their level
of use. For instance, a product which offers additional
benefit, perhaps through higher HIV protection, protec-
tion against sexually transmitted infections (STI) or
contraceptive properties, may have higher uptake and
use. It is possible that new or existing products could in-
corporate these characteristics [29], and through doing
so may achieve higher uptake and HIV prevention im-
pact. For example, regular users of contraceptive prod-
ucts may not value HIV protection enough to take daily
PrEP, but if HIV protection was built into a contracep-
tive product, considerable additional impact could be
achieved [30]. Understanding what people value about
potential prevention methods could make prevention
products more responsive to end-user needs.
Evaluating how different product characteristics may
impact demand for, or choices between products is chal-
lenging before they are introduced, particularly with no
comparable products on the market. Economic theory
suggests that consumer’s choices give insights into their
underlying preferences, and the field of choice modelling
has advanced to explore how choice data can be used to
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choice data exist to explore “revealed” preferences, i.e.
observed use behaviour, one option is to elicit “stated”
preferences. This can be done through a discrete choice
experiment (DCE) where survey participants choose be-
tween hypothetical alternatives, each representing a spe-
cific product or service that is described by a number of
more and less desirable attributes. Respondents are pre-
sented with a series of such choices, normally 8–10. An
example of a DCE task is displayed in Fig. 1. By analys-
ing the trade-offs respondents make, researchers can
quantitatively explore what drives individual decision-
making and the relative strength of preferences. DCEs
are becoming increasingly popular in health services
research [33–35].
In this analysis, we develop a previously published
model [30, 36] to project the uptake of new and future
products amongst young and adult women. We build on
our published cost-effectiveness analysis [36] to look in
detail at how the uptake of existing and new prevention
products may be influenced by what products are already
available, the prevention characteristics of those products,
and the different preferences of adolescent and adult
women. We also consider how the addition of these new
products may reduce the prevention gap amongst adoles-
cent and adult women, and how their additional preven-
tion characteristics may contribute to this.
Methods
We used a DCE to project the uptake of oral PrEP, which
is now being rolled out in South Africa, and two other
ARV-based HIV prevention products in the order that
they are likely to become available on the market (Table 1):Fig. 1 Example of a DCE task. Attributes shown in figure are just for illustra
the product attributes given in Table 2vaginal ring and injectable long-lasting ARV agents. We
assessed how each product will affect the uptake of exist-
ing products, including the male condom, and how the
characteristics of that product in terms of pregnancy and
STI protection will affect its uptake. We assumed a base-
line where only the male condom is available, with HIV
efficacy of 85% (66–94% in uncertainty analysis) [37, 38]
as well as STI and pregnancy protection, but only used in
some sex acts. We then consider oral PrEP with just HIV
efficacy, which is currently being introduced (phase 1).
For oral PrEP, we assumed an HIV efficacy of 61% (40–
75% in uncertainty analysis) as found among adherent
women in a recent meta-analysis [10]. We then assume
that the vaginal ring is introduced (phase 2) with HIV effi-
cacy of 55% (31–71% in uncertainty analysis), as found
among older women in a recent trial [19]. Lastly, we as-
sumed injectable ARV agents would be introduced (phase
3).
Although injectable ARVs have not yet been evaluated
among women in HIV prevention trials, we assumed a
higher HIV efficacy of 75% (55–90% in uncertainty ana-
lysis) because there should be fewer issues of adherence.
For oral PrEP, vaginal ring and injectable ARVs, we ini-
tially assume no pregnancy or STI protection (in phase 3),
but then assess in phase 4 how uptake would increase if
they also had pregnancy protection or both pregnancy and
STI protection with the same efficacy. This was done to
reflect current products in development as well as other
possible products not yet in development [39].
Summary of discrete choice experiment
The DCE protocol and results are described elsewhere
[40, 41]. In brief, a DCE was developed to elicit statedtion, and show that DCE’s consider options that are much wider than
Table 1 Scenarios modelled
Products HIV protection Pregnancy protection STI protection
Phase 1 Oral PrEP X
Phase 2 Oral PrEP X
Vaginal ring X
Phase 3 Oral PrEP X
Vaginal ring X
Injectable ARVs X
Phase 4 Oral PrEP X Xa Xa
Vaginal ring X Xa Xa
Injectable ARVs X Xa Xa
aTwo scenarios are modelled for Phase 4, one including just pregnancy protection and another including both pregnancy and STI protection
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attributes varying as in Table 2. The DCE options were
developed through qualitative focus groups, literature re-
view, and extensive piloting. Primary data collection oc-
curred in October to December 2015 in Ekurhuleni
(south-east of Johannesburg, South Africa) in a peri-
urban area. The study was approved by the University of
the Witwatersrand Human Research Ethics Committee
and the Research Ethics Committee at the London
School of Hygiene and Tropical Medicine. All participa-
tion in the DCE, alongside supporting qualitative studies,
was voluntary and subject to completion of written in-
formed consent.
Data were gathered through a randomised household
survey from 158 adult females (age 18 or over) and 204
adolescent girls (aged 16–17) who self-reported HIV
negative status [42]. DCE analyses are based on the as-
sumption that people maximise their utility [31]. By ana-
lysing how respondents make choices over the
hypothetical choice sets in the DCE, we can infer how
important different attributes are to their decision-
making. Further information on how this was done can
be found in the Supplementary material. This method of
simulating from choice data has been termed predicted
probability analysis, and has been applied in various
fields [43, 44]. We use a nested logit model for predic-
tion, which in part accounts for the assumption of inde-
pendence of irrelevant alternatives, a limitation of manyTable 2 Base case product characteristics. Simulated characteristics
Product HIV efficacy
(bounds used in uncertainty
analysis – uniform distribution)
Oral pre-exposure prophylaxis 61% (40–75%)
Vaginal Ring 55% (31–71%)
Injectable ARVs 75% (55–90%)
Condom 85% (66–94%)
No condom 0choice models. In health, there is evidence that hypo-
thetical choices in DCEs correlate with real-world
choices [45].
In this analysis, we developed separate uptake projec-
tions for adolescent and adult women and considered
the following ARV-based prevention products - oral
PrEP, vaginal ring and injectable ARV agents. We under-
took separate analyses for adolescent and adult women
because these subgroups have differing levels of HIV risk
[46, 47] and sexual risk behaviours [46], with the adverse
effects of these risks being different [48]. We also ex-
pected them to have different preferences for sexual and
reproductive health products, dissimilar levels of health
service utilisation [46], and would need tailored inter-
ventions to meet their needs [49]. Uptake projections
were produced for women using or not using condoms
in their last sex act, which were combined to give the
overall degree to which each product would be used.
Uptake projections were made for the four phase scenar-
ios described above.
Estimating prevention protection
We adapt a formula from our previous paper to estimate
the short-term impact of a number of HIV prevention
products on the average level of protection that a
woman has (defined as the prevention protection) [30].
This measure gives the overall average decrease in the
probability of HIV transmission in an average sex actin parentheses
STI efficacy Contraceptive
protection
Frequency
of use
N (Y) N (Y) Daily
N (Y) N (Y) Monthly
N (Y) N (Y) Every three months
Y Y Coital
N N Coital
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cacies being used at different levels. For a single product
x, we assume the average protection against HIV, Px,
from using product x is the product of its efficacy, Ex,
and uptake (or use) Ux,
Px ¼ ExUx: ð1Þ
In this analysis, we assume Px is the existing protection
provided by male condoms (defined as product x). Our
DCE then gives projections of the degree to which con-
dom users and non-condom users uptake each product
(from 1 to 3 products), and for prior condom users the
degree to which the woman would still use condoms (ε,
assumed to be independent of product) in addition to
the new product. For n new products, each with efficacy
Ei and uptake Uci and Unci (i = 1..n) among condom
users and non-condom users, respectively, the overall
protection provided (Pn) is estimated as:
Pn ¼ Ux½ 1 − 1 − εð Þ X
i¼1::n
Uci
 !
Ex þ 1 − εð Þ
X
i¼1::n
EiUci
þ ε
X
i¼1::n
1 − Exð ÞEiUci þ 1 −Uxð Þ X
i¼1::n
EiUnci
ð2Þ
It is important to note that the uptake of each product
(Uci and Unci) will depend not only on its HIV efficacy
but also on whether they provide STI and/or pregnancy
protection. The prevention protection provided by dif-
ferent products is assumed to be additive if they are not
used together, which was assumed for all ARV-based
products. However, when condoms were used with a
new product, the new product was assumed to decrease
the remaining risk still existing after the protection pro-
vided by the condom was accounted for.
The formula in eq. 2 is used to estimate the prevention
protection provided in each phase by the available com-
bined prevention products. In each phase, we estimate
the degree to which the addition of a new product in-
creases the existing prevention protection among young
and adult women in South Africa, and how the non-HIV
characteristics of that product improve its HIV effective-
ness through increasing uptake. The scenarios modelled
are shown in Table 1, using the uptake projections from
the DCE and the efficacy estimates in Table 2. Based on
data from the DCE, we assumed 43% condom use in last
act among adult women and 65% among adolescents at
baseline [41]. This is comparable to condom use estimates
from the 2017 South African National HIV prevalence, in-
cidence, behaviour and communication survey [47].Uncertainty analysis
To assess the robustness of our prevention projections,
we undertook an uncertainty analysis to see how uncer-
tainty in the product HIV efficacy (Table 2) and result-
ing DCE uptake projections (from the 95% confidence
intervals for the model) affect the prevention protection
achieved in an average sex act, the degree to which each
product contributes to the prevention protection, and
the importance of pregnancy and STI protection for in-
creasing the protection provided by the products. We
considered the scenario where all 3 products have been
introduced (phases 3 and 4) with oral PrEP, vaginal ring
and injectable ARVs either having no pregnancy or STI
protection, just pregnancy protection, or both STI and
pregnancy protection. For uptake predictions, Monte
Carlo simulation was used with 1000 independent draws
from the normal distributions of DCE parameters, sim-
ultaneously varying product efficacy according to a uni-
form distribution between upper and lower bounds in
Table 2.
Results
Projected uptake of products in adolescent and adult
women
The DCE suggests that the patterns of uptake of oral
PrEP, vaginal ring, and injectable ARVs will depend on
the target population using the products, the availability
of other products, and the characteristics of the product
(Fig. 2). However, condom use remains fairly stable irre-
spective of what other products are available, with it
only reducing by up to 8 percentage points, from 43 to
39% in adult women and 65 to 57% in adolescents, when
all three additional products are available, and they all
provide protection against pregnancy and STIs.
Among adult women, we predict that 17% of adult
women would use oral PrEP if it was the only product
available (other than condoms) and was just HIV effica-
cious (phase 1). However, its use would decrease by a
third in phase 2 when the vaginal ring is also available,
with both products being similarly popular (used by 12–
13% of adult women) if they are just HIV efficacious. In
phase 3, the projected uptake of both oral PrEP and va-
ginal ring decreases by two-thirds (< 4.5% use either) be-
cause many (16%) women switch to using injectable
ARVs. Lastly, in phase 4, when the different products
now provide multipurpose protection, our projections
suggest adult women in South Africa will favour inject-
able ARVs with 20% using this product if it provides
pregnancy protection and 24% if it also provides STI
protection, while less than 5% use oral PrEP or the vagi-
nal ring.
In contrast to adult women, adolescent women have
a much stronger preference for products providing preg-
nancy protection (and STI protection to a smaller
Fig. 2 Projected uptake of oral PrEP, vaginal ring and injectable ARVs amongst adolescent (a) and adult women (b), and resulting effect on levels
of condom use. The percentage of women using no product for each phase is also shown. The products are assumed to be introduced in four
phases, with oral PrEP becoming available first, then the vaginal ring, and injectable ARVs (these 3 are assumed to be just HIV efficacious), and
then phase 4 has the same products but with pregnancy and STI efficacy included. a. Adolescent women. b. Adult women
Vickerman et al. BMC Infectious Diseases          (2020) 20:704 Page 6 of 11extent), with a product’s HIV efficacy being relatively
less important. For instance, in phase 4 the uptake of
each product increases nearly 4-fold when pregnancy
protection is included compared to if the products just
provided HIV protection, and increases a further 30% if
STI protection is also included. For injectable ARVs this
means that uptake increases from 3.9% if they are just
HIV efficacious, to 15% if they also provide pregnancy
protection and 19% if they provide pregnancy and STI
protection. Importantly, there is very little uptake of any
product if it is only HIV efficacious with at best 5% up-
take being achieved with oral PrEP in phase 1 and 2. In
terms of product preferences, adolescent women seem
to have little preference for the vaginal ring even when it
has pregnancy and STI efficacy. As seen for adult
women, injectable ARVs seem to be the most widelypreferred product by these populations in South Africa,
although oral PrEP is still liked.
Importantly, even when all three new products are
available a sizeable proportion of adolescent (14–30%)
and adult (29–38%) women are not inclined to use any
form of protection, irrespective of whether the products
also provide pregnancy and STI protection.
Projected protection provided in adolescent and adult
women
When we incorporate the DCE uptake projections into
our model, it suggests that the introduction of these
products in adolescent women will only contribute
markedly to the existing protection supplied by condoms
(Fig. 3a) if multiple products are introduced and they
also provide protection against pregnancy (and STIs to a
Fig. 3 Projected overall protection provided by introducing oral PrEP, vaginal ring and injectable ARVs amongst adolescent (a) and adult women
(b), in addition to baseline levels of condom use. The products are assumed to be introduced in four phases, with oral PrEP becoming available
first, then the vaginal ring, and injectable ARVs (these 3 are assumed to be just HIV efficacious), and then phase 4 has the same products but with
pregnancy and STI efficacy included. a. Adolescent women. b. Adult women
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tion provided by solely HIV efficacious products is at
best 3 percentage points, whereas the introduction of
multiple products that also have pregnancy protection
increases the protection supplied by 11 percentage
points (from 55 to 66% in absolute terms) and 14 per-
centage points (to 69%) if they also protect against STIs.
In contrast, greater benefit can be achieved through
introducing solely HIV efficacious products among adult
women (Fig. 3b), but less additional impact is achieved if
they also incorporate pregnancy and STI protection. Forinstance, introducing just oral PrEP (phase 1) is pro-
jected to increase the protection provided to adult
women from 37 to 44% if it is just HIV efficacious; in-
creasing to 47% if the vaginal ring is introduced and 50%
if injectable ARVs are also introduced. However, incorp-
orating pregnancy protection to these three products
only increases the protection to 52, and 56% if they also
protect against STIs.
Importantly, as also highlighted in the uptake projec-
tions, our modelling here suggests that even with intro-
duction of three new multi-purpose HIV prevention
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with the imperfect use and efficacy of these products
resulting in at least 31 and 44% of adolescent and adult
women’s baseline transmission risk still remaining,
respectively.
Uncertainty analysis
Consistent with our point projections for adolescent
women, our uncertainty analysis found that 59–62% of
model runs projected that the addition of pregnancy
protection was more important for increasing uptake
than HIV efficacy for oral PrEP, vaginal ring and inject-
able ARVs, with its addition increasing the overall pro-
tection provided by these products by 138% (IQR 71–
244%) compared to if the products were just HIV effica-
cious. Additionally, injectable ARVs were the most pre-
ferred product for adolescent women in 80% of model
runs, while the vaginal ring was least popular in 95% of
model runs. Uncertainties in the uptake projections re-
sulted in moderate uncertainty in the overall protection
provided by the three products, as can be seen in Sup-
plementary Fig. 1a.
Similarly, the results of our uncertainty analysis for
adult women were also generally consistent with our
point projections, with HIV efficacy being the most im-
portant attribute of a product in 94% of model runs, and
injectable ARVs being the most preferred product in
99% of model runs. Supplementary Fig. 1b shows that
there was also moderate uncertainty in the protection
projections for adult women, but as for the point projec-
tions less was gained from incorporating pregnancy and
STI efficacy, with the addition of these attributes in-
creasing the protection provided by solely HIV effica-
cious products by 41% (IQR 26–71%).
Discussion
Oral PrEP is now available in many settings, while other
new ARV based HIV prevention products should be-
come available in the next 5–10 years [17, 18, 25]. With
the concurrent scale-up of ART, this has raised opti-
mism that we can reduce HIV transmission to low levels
by 2030, as advocated by the World Health Organisation
[50]. To achieve this, we need high uptake of new pre-
vention products in the groups with highest burden,
such as young and adult women [46, 51]. Although trials
and demonstration projects provide insights into how
new products may be used [13, 52], they cannot give in-
sights for products that are in earlier stages of develop-
ment or how including other product characteristics
may affect levels of use.
Our analyses help to fill this knowledge gap. They em-
phasise the importance of multi-purpose prevention
products for ensuring high uptake and protection
amongst adolescent women, and for improving uptakeand protection amongst adult women. Also, adolescents
and adult women are likely to need a range of products,
with their ultimate preference being towards injectable
ARVs, less so oral PrEP and the vaginal ring, and for ad-
olescents any product that provides pregnancy protec-
tion. The development of a jointly HIV and pregnancy
protective product is critical to meet the needs of ado-
lescent women who are at heightened risk of HIV, since
preferences for contraceptive products are particularly
great in this group.
Importantly, irrespective of what products are intro-
duced, a large prevention gap (> 20% women remain un-
protected) may remain among both groups following the
introduction of these new products. This highlights the
importance of interventions to encourage greater use of
new ARV-based prevention products amongst women;
one of the aims of the Dreams intervention for adoles-
cent women in sub-Saharan Africa (https://www.state.
gov/pepfar-dreams-partnership/). Possible strategies to
encourage greater uptake include demand creation in-
volving positive communication and awareness raising,
while greater adherence could be promoted through
PrEP adherence support or peer support groups, while
integrating PrEP visits with other reproductive health
services may promote greater attendance at visits [13].
Limitations
Our analysis has limitations. Firstly, uptake projections
from a DCE are theoretical and not based on actual
long-term use of a product. Although real levels of prod-
uct use are likely to differ from our projections, it is re-
assuring that they agree qualitatively with the observed
low uptake of oral PrEP and vaginal ring among young
women [11, 12, 19, 53], and the high acceptability of in-
jectable contraceptives amongst South African women
[12]. They also agree with other studies that have
emphasised the preference for multipurpose prevention
technologies (MPTs) in women [54–56]. However, it is
still important to remember the hypothetical nature of
our study, with our uptake projections likely being opti-
mistic compared to real levels of use. This was seen for
PrEP, where high levels of acceptability prior to its intro-
duction [57, 58] has not translated into similar levels of
use among women [13, 59]. In other health areas, DCEs
have been shown to predict opting-in behaviours with a
88% sensitivity indicating that, although imperfect, they
can be useful tools when the alternative is to make as-
sumptions without data from end-users [45].
Secondly, it is possible that the high acceptability of
injectable ARVs among adult women may not be
generalizable to other settings where there has not been
the same history of using injectable contraceptives.
However, this may not be an issue because other studies
have also suggested that injectable ARV may be more
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volvement and could be long-lasting [14, 56].
Thirdly, our impact projections are likely to be con-
servative because we did not account for the add-
itional benefit that an STI efficacious product may
have on HIV transmission through reducing STI
transmission. Conversely, we did not account for a
possible increase in HIV transmission risk resulting
from combining hormonal contraceptives with an
ARV-based product, in line with the results of the
ECHO trial [60].
Comparison with other analyses
Other modelling has projected the impact of combin-
ation HIV prevention products, using expert opinion
and trial data to estimate the likely level of use of new
products [25–28]. Our uptake projections are generally
consistent or more conservative than were used in these
analyses, and differ by population group. These differ-
ences highlight that we should be wary of using expert
opinion to guide uptake scenarios because they are not
based on actual user preferences and could overplay the
likely impact of new products. There was further novelty
to our analysis because we also assessed the effect on
uptake of developing MPT products with pregnancy
and STI protection as well as HIV efficacy. This has
not been done in previous analyses except our previ-
ous cost-effectiveness analysis [36], which showed in-
corporating pregnancy protection could improve the
cost-effectiveness of HIV prevention products.
Implications and conclusions
High levels of HIV transmission exist among women in
sub-Saharan Africa, with existing interventions being in-
sufficient to reduce their heightened risk. It is hoped that
newly emerging ARV-based prevention products may fill
this prevention gap. Our projections suggest this could
be the case, but only if these new products have multiple
facets for adolescent women, incorporating pregnancy
and STI protection for maximising their uptake. Indeed,
a product’s non-HIV characteristics may be more im-
portant for adolescent women than its HIV efficacy, with
little uptake and impact being achieved otherwise. This
is less important for adult women where HIV efficacy is
more important. It is uncertain why adult women do not
view STI protection as importantly as HIV protection
when choosing between products, although it may be
partly due to having less knowledge about STIs [61]
and/or HIV being seen as a more serious disease than
other STIs. It is also important that the full range of
products are available to women for maximising uptake,
with injectable ARV agents probably being most popular
for adolescent and adult women. Importantly, though,
our projections suggest that in neither adolescent noradult women will the introduction of these products re-
sult in the overall average protection being higher than
60%. This means that a substantial portion of acquisition
risk will still exist, emphasising the need for interven-
tions to increase uptake of new products and the im-
portance of scaling up HIV treatment.
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